Introduction
============

*Klebsiella pneumoniae* (KP) is a pathogen that is mainly associated with community and nosocomial infections; after *Escherichia coli*, it is the second most common pathogen that leads to gram-negative bloodstream infections (BSIs).[@b1-idr-11-595],[@b2-idr-11-595] With more and more KP isolates producing extended-spectrum β-lactamase, and therefore exhibiting resistance to many penicillin and cephalosporin antibiotics, carbapenems are the most widely used first-line antibiotics for such infections.[@b3-idr-11-595] However, the widespread use of these antibiotics has caused the emergence of carbapenem-resistant strains, mostly because of the propagation of carbapenemhydrolyzing β-lactamases like the KP carbapenemase (KPC). KPC-producing KP was first reported in 1996,[@b4-idr-11-595] and in the People's Republic of China, the first KPC-positive KP isolates were found in intensive care unit (ICU) from a 75-year-old patient in 2004;[@b5-idr-11-595] it has subsequently emerged as a global health care threat and is now endemic in many countries.[@b6-idr-11-595]--[@b8-idr-11-595]

As well as being a serious public health issue and infection control challenge, carbapenem-resistant *Klebsiella pneumoniae* (CRKP) is related to higher treatment failure rates, mortality, and cost.[@b7-idr-11-595],[@b8-idr-11-595] Prior studies show that BSIs caused by carbapenem-nonsusceptible *Klebsiella pneumoniae* (CnSKP) are associated with disappointing outcomes; the hospital death rates associating with these infections range from 40% to 72% compared with 20% to 30% in patients with carbapenem-susceptible *Klebsiella pneumoniae* (CSKP) infections.[@b9-idr-11-595]--[@b12-idr-11-595] Furthermore, being older, hospital-acquired infections, ICU stay, illness severity, and inappropriate regimens have been identified as risk factors contributing to increased mortality rates in patients with CnSKP-BSI.[@b13-idr-11-595],[@b14-idr-11-595]

In previous retrospective studies, tigecycline combined with colistin, carbapenems, or aminoglycosides was found to be the most common regimen used for the management of carbapenem-resistant Enterobacteriaceae infection,[@b15-idr-11-595],[@b16-idr-11-595] although the most beneficial of the regimens has not yet been identified.[@b12-idr-11-595],[@b17-idr-11-595],[@b18-idr-11-595] Therefore, studies recognizing risk factors for the development of CnSKP-BSI and exploring the most effective therapeutic approaches are required. In this study, a retrospective group of patients with KP-BSIs were analyzed to identify the risk factors accompanied by CnSKP, explore prognosis, and evaluate treatments.

Methods
=======

Study design
------------

This retrospective study was conducted at the First Affiliated Hospital, College of Medicine, Zhejiang University, a 2500-bed teaching hospital in Eastern China, after receiving approval from the Research Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University. This study did not directly interfere with the patients or show the patients' name, medical record number, or other personal information. Moreover, there was no adverse effect on the rights of patients; therefore, consent to review their medical records was not required by the Institutional Review Board. The study population comprised patients treated for BSI caused by KP (KP-BSI) between January 1, 2013, and December 31, 2015. Patients whose age was \<16 years were excluded. If there were more than two episodes of KP-BSI in one patient, only the first episode was included. For the mortality analysis, patients who did not accept \>48 hours of antimicrobial treatment for any reason were excluded. Patient demographics; clinical and microbiological data; laboratory analyses; data on antimicrobial therapy, underlying diseases, and comorbidities; and other relevant information were retrieved from the hospital information system. Illness severity was assessed by using the Acute Physiology and Chronic Health Evaluation (APACHE) II scores calculated when BSIs attack.[@b19-idr-11-595] Charlson comorbidity index was used to determine comorbid conditions.[@b20-idr-11-595]

Data analysis
-------------

In order to assess treatment outcomes, 30-day mortality was investigated. As illustrated in [Figure S1](#SD1-idr-11-595){ref-type="supplementary-material"}, a three-part analysis was conducted: 1) to evaluate the risk factors associated with CnSKP-BSI, 428 patients were divided into CSKP and CnSKP patient groups; 2) to explore the prognosis of KP-BSI and antibiotic treatment programs, the patients were categorized as survivors if they were alive after 30 days of infection or nonsurvivors if they were not (patients whose treatment time was \<48 hours were excluded); and 3) to assess the risk factors associated with the 30-day mortality and treatment among patients with CnSKP-BSI, a case-controlled study was conducted.

Microbiological assessment and definition of terms
--------------------------------------------------

KP-BSI onset was defined as the collection date of the first positive blood culture. The probable infectious source was determined by using Centers for Disease Control and Prevention/National Healthcare Safety Network surveillance definitions; primary BSI was recorded if no source was identified.[@b21-idr-11-595] When an absolute neutrophil count was \<1500/μL on BSI onset, it was defined as neutropenia. Steroid therapy was defined as \>20 mg/day prednisone or its equivalent administered for ≥7 days. Antimicrobial drug exposure referred to the use of antibiotics for \>72 hours at any point 2 weeks prior to BSI diagnosis. Empirical therapy indicated all antimicrobial drugs administered to treat a suspected BSI. Definitive therapy referred to antimicrobial therapy administered after the susceptibility testing results were available and was classified as "appropriate" if an adequate dose of at least one drug was administered to which the pathogen was susceptible (as indicated by in vitro susceptibility testing) or "inappropriate" if these criteria were not met.[@b22-idr-11-595] Overall mortality included all causes of death during hospitalization. During the study period, tigecycline was used to treat CnSKP-BSI, and its dosing was classified into conventional (100 mg loading dose, followed by 50 mg every 12 hours) or high dose (100 mg every 12 hours).[@b23-idr-11-595]

The identification and antimicrobial susceptibility of KP were determined by using the Vitek2 system (bioMérieux, Marcy-l'Etoile, France). The minimum inhibitory concentration (MIC) of tigecycline was determined by using standard broth microdilution tests with fresh (\<12 hours) Mueller--Hinton II Broth (cation-adjusted; Solarbio Science and Technology Ltd., Beijing, People's Republic of China). According to the guidelines of the Clinical and Laboratory Standards Institute standards (2015), carbapenem-non-susceptibility is defined as an MIC of ≥1 mg/L for ertapenem or ≥2 mg/L for imipenem or meropenem.[@b24-idr-11-595] The US Food and Drug Administration (FDA) break points were used to judge tigecycline susceptibilities.[@b25-idr-11-595]

Statistical analysis
--------------------

In order to evaluate continuous variables, the Student's *t*-test (for normally distributed variables) or Mann--Whitney *U* test (for variables that are not normally distributed) was used. Categorical variables were analyzed by using the χ^2^ test or two-tailed Fisher's exact test appropriately. For continuous variables, results are expressed as median (interquartile range) or mean ± standard deviation, and categorical variables are expressed using the percentages of the group. The strength of all associations that emerged was determined using odds ratios (ORs) and 95% confidence intervals (CIs). Two-tailed tests were used to determine statistical significance. For multivariate analysis to identify independent predictors, variables with a *P*-value ≤0.05 in the univariate analysis were used in binary logistic regression. Kaplan--Meier product limit method was used to estimate the survival distribution function; nonparametric (log rank and Wilcoxon) tests were used to compare survival functions in different groups. In all analyses, *P*-values ≤0.05 were considered significant. All statistical analyses were carried out by using the SPSS Version 23.0 (IBM Corporation, Armonk, NY, USA).

Results
=======

During the 3-year study period, 436 patients with at least one positive blood culture for Klebsiella were evaluated; 8 patients aged \<16 years were excluded. Of the 428 patients included, 31.5% (n=135) had CnSKP. The overall incidence of KP-BSI was 0.154/1000 patient-days during the 3-year period ([Figure S2](#SD2-idr-11-595){ref-type="supplementary-material"}). The overall incidence of CnSKP-BSI increased from 0.037/1000 patient-days in 2013 to 0.062/1000 patient-days in 2015, with the highest incidence occurring in the ICU (1.030/1000 patient-days). The results of antimicrobial susceptibility testing showed that the resistance rate of KP isolates to most antimicrobial agents was 35.0%--60%.

[Table 1](#t1-idr-11-595){ref-type="table"} shows the patient demographics and clinical characteristics. Regarding the probable infectious source of KP-BSI, intra-abdominal infection was most common (38.3%), followed by respiratory tract infection (31.8%) and primary bacteremia (17.5%). The overall all-cause 30-day mortality rate of KP-BSI patients was 29% (124 of 428); this was found to be significantly higher in patients with CnSKP-BSI (58.5%) than in those with CSKP (15.4%). Survival curve analysis confirmed the higher risks of mortality related to CnSKP-BSI (χ^2^=63.180, *P*\<0.001; [Figure 1A](#f1-idr-11-595){ref-type="fig"}).

Risk factors associated with the development of CnSKP-BSIs
----------------------------------------------------------

The univariate analysis showed that, compared with patients with CSKP-BSIs, those with CnSKP-BSIs were more likely to have nosocomial infection, respiratory tract origination, prior hospitalization, prior ICU hospitalization, or previous transplantations or to have undergone a nonsurgical invasive procedure, hemodialysis, chemotherapy, or radiotherapy. They also had lower total protein and high APACHE II scores and were more likely to have received corticosteroid therapy, immunosuppression, or prior exposure to drugs in the previous 14 days. In the multivariate analysis, logistic regression analysis ([Table 1](#t1-idr-11-595){ref-type="table"}) showed the following factors to be independent risk factors for CnSKP-BSIs: hospitalization within 90 days before infection (OR =2.395, *P*=0.004), prior Foley catheterization (OR =5.277, *P*\<0.001), immunosuppressive exposure (OR =4.093, *P*=0.001), prior use of antibiotics within 14 days prior to BSI (OR =2.739, *P*\<0.001), previous carbapenem exposure (OR =4.591, *P*\<0.001), pulmonary disease comorbidity (OR =2.599, *P*=0.008), and high APACHE II score (OR =1.100, *P*=0.001).

Risk factors for 30-day mortality in patients with KP-BSI
---------------------------------------------------------

Of the 428 patients, 292 were classified as survivors and 78 as nonsurvivors; 58 patients were excluded as their treatment time was \<48 hours. In the multivariate analysis ([Table 2](#t2-idr-11-595){ref-type="table"}), factors independently associated with a higher risk of mortality were as follows: neutropenia, multiple organ dysfunction, respiratory failure, CnSKP infection, high APACHE II score, and tigecycline therapy after BSI. As shown in [Table 2](#t2-idr-11-595){ref-type="table"}, carbapenem (n=254, 68.6%) was the most commonly used agent, followed by β-lactam and/or β-lactamase inhibitor (n=180, 48.6%) and tigecycline (n=84, 22.7%). Among KP-BSI patients treated with tigecycline, 48.8% received conventional dosing and 51.2% were treated with the high-dose regimen; no significant differences were seen in terms of 30-day mortality between the groups ([Figure 1B](#f1-idr-11-595){ref-type="fig"}). For patients with APACHE II scores \<15 at the onset of bacteremia, the 30-day mortality rate of patients receiving tigecycline was higher than that of patients receiving other antibiotics (45.3% vs 7.7%; [Figure 1C](#f1-idr-11-595){ref-type="fig"}).

Risk factors for 30-day mortality in patients with CnSKP-BSI
------------------------------------------------------------

A total of 107 patients (excluding 28 patients with CnSKP-BSI who died within 48 hours of diagnosis) were included in this analysis; 65.4% of patients stayed in the ICU after infection, and the 30-day mortality rate was 48.6%. [Table S1](#SD3-idr-11-595){ref-type="supplementary-material"} shows the main characteristics of the CnSKP-BSI survivor and nonsurvivor subgroups. The logistic regression analysis indicated that prior indwelling central venous catheter (OR =3.704, 95% CI =1.325--10.356, *P*=0.013), multiple organ dysfunction (OR =5.498, 95% CI =1.727--17.504, *P*=0.004), and a high APACHE II score (OR =1.154, 95% CI =1.054--1.263, *P*=0.002) were independent risk factors for 30-day death from CnSKP infection.

The assessment of empirical treatment in the CnSKP-BSI group showed that 69 (64.5%) patients received at least two drugs within 48 hours of the onset of bacteremia, while 38 (35.5%) patients received monotherapy; no significant differences in the 30-day mortality were found among these two subgroups (36.8% vs 55.1%, *P*=0.071) or between those who received appropriate empirical treatment versus inappropriate empirical treatment (*P*=0.896). For definitive treatment, 61 (55.2%) patients received therapy with no active drug due to multiresistance, 37 patients (34.6%) received one active drug, and 9 patients (8.4%) received at least two active drugs; no significant differences were found in mortality between appropriate definitive treatment and inappropriate definitive treatment (54.3% vs 44.3%, *P*=0.220).

Discussion
==========

KP is one of the most important pathogens of nosocomial infection, and while carbapenem antibiotics are an effective treatment approach,[@b3-idr-11-595] surveillance data showed that the rate of CnSKP has increased year on year in the People's Republic of China, an has increased worldwide over the past 10 years.[@b6-idr-11-595]--[@b8-idr-11-595] In the present study, we also observed an increase in CnSKP-BSI during the study period, rising from 26.9% in 2013 to 33.3% in 2015. With the emergence of antibiotic-resistant strains, effective clinical treatment and control of infection are likely to present an increasing challenge.

This study represents the largest 3-year evaluation of KP-BSIs in Mainland China up to present. Data from 428 KP-BSI patients were evaluated, demonstrating prior hospitalization, urinary catheterization, and high APACHE II scores to be independent risk factors for the development of CnSKP-BSI, which reflects risk factors reported in previous studies.[@b13-idr-11-595],[@b14-idr-11-595] The highest incidence of CnSKP infections was observed in the ICU, with 65.4% of CnSKP-BSI patients admitted to the ICU before infection. It is well known that KP often colonizes in the respiratory tract or intestinal tract and can invade the body when immunity is compromised. In the present study, recent solid organ or stem cell transplantation was associated with invasive CnSKP infection independently, and prior studies showed KP infection to be a greater cause of BSIs in liver transplant recipients.[@b11-idr-11-595] In our hospital, we found the second highest incidence of CnSKP-BSI in the department of liver transplantation, which may be due to having frequent hospitalization of the patients and long-term exposure to immunosuppressive agents.

Antimicrobial use prior to BSI is known as an important factor in drug-resistant infections,[@b3-idr-11-595],[@b11-idr-11-595] although some studies showed no association between CnSKP infection and prior antibiotic therapy.[@b14-idr-11-595] Our results also demonstrated that the use of cephalosporin, β-lactam and/or β-lactamase inhibitors, fluoroquinolones, tigecycline, or carbapenem in the 14 days prior to BSI differed between the CSKP and CnSKP groups, with multivariate analysis showing that antibiotic exposure, particularly carbapenem use, in this period was an independent risk factor for CnSKP.

In order to explore the high mortality rate associated with KP-BSI further, we evaluated patient characteristics and treatments. In this study, the 30-day death rate associated with CnSKP-BSI was 58.5%, significantly higher than that associated with CSKP (15.4%); these data are similar to figures found in previous reports.[@b9-idr-11-595],[@b10-idr-11-595] In addition, resistance to carbapenem was associated with an increased risk of mortality, which is in contrast to some previous studies.[@b13-idr-11-595] As previously reported,[@b9-idr-11-595],[@b22-idr-11-595] multiple organ dysfunction, respiratory failure, or high APACHE II scores were found as independent predictors of death; our analysis also found that KP-BSI patients with neutropenia were likely to have a poor outcome.

Tigecycline has a broad spectrum of action and excellent in vitro antimicrobial activity. It has been commonly used in infections caused by mixed pathogens or multidrug-resistant pathogens and is approved primarily for use in respiratory tract infections, complicated skin and skin structure infections, and complicated intra-abdominal infections caused by Enterobacteriaceae. Because of the lack of appropriate antibiotics for the treatment of multidrug-resistant bacteria such as CnSKP, tigecycline has become more widely used, although its efficacy in the treatment of KP-BSI remains controversial.[@b15-idr-11-595],[@b16-idr-11-595],[@b26-idr-11-595]--[@b28-idr-11-595] The present study demonstrated significantly higher mortality rates in the tigecycline group than in controls (51.2% and 12.2%, *P*\<0.001); for patients with APACHE II scores \<15, the 30-day mortality rate of patients receiving tigecycline was 45.3%, versus 7.7% in patients receiving other antibiotics. These data are consistent with the FDA warning and a previous meta-analysis,[@b26-idr-11-595],[@b28-idr-11-595] which showed that the proportion of patients with septic shock was significantly higher in those treated by tigecycline than in the controls (relative risk =7.01). For patients whose infection is not resolved by conventional doses of tigecycline, an increased dose is often used, which is an approach that has also been recommended in a recent consensus statement.[@b15-idr-11-595] However, a study of mortality among patients receiving conventional versus higher-dose regimens suggested that differences were dependent on the underlying infection severity, and there is limited clinical evidence to support high-dose tigecycline regimens.[@b23-idr-11-595] Indeed, there were similarities in mortality between KP-BSI patients with APACHE II scores \<15 treated with conventional dosing of tigecycline and higher dosing regimens in our analysis. Based on these observations, tigecycline does not appear to be superior to standard antimicrobial agents to treat KP-BSI, and physicians should exercise caution when selecting tigecycline for the therapy of multidrug-resistant infections.

In this study, deaths among patients with CnSKP-BSI were directly and independently related to the severity of infection, multiple organ dysfunction, and high APACHE II score. At present, a best practice treatment program for patients with CnSKP-BSI has not been established. In this study, most patients received carbapenem, with mono-therapy accounting for 23.9% of regimens and combination treatments accounting for 76.1%; no significant difference in CnSKP 30-day mortality was found among the two treatment regimens. The previous examination of the outcome of KPC-KP bacteremia in 125 patients treated at three large Italian teaching hospitals showed the overall 30-day mortality rate to be 42%, while mortality in patients receiving colistin, tigecycline, and meropenem combination regimens was significantly lower (34%, vs 54% with monotherapy; *P*=0.02).[@b22-idr-11-595] By contrast, a review of 141 patients with CRKP-BSIs found that there were similarities in the 30-day mortality of patients who were treated with monotherapy and those with combination regimens (38% vs 26%, *P*=0.1).[@b12-idr-11-595] Several clinical studies suggest that CRKP-BSI patients who were treated by carbapenem-containing combination regimens have significantly lower mortality rates than those treated by non-carbapenem-containing regimens, especially in cases where the MIC of KP was \<4 mg/L.[@b29-idr-11-595],[@b30-idr-11-595] In patients treated with carbapenem combination therapy, we found successful treatment in 75% of patients with meropenem MIC ≤4 μg/mL, compared with 47.9% with meropenem MIC ≥8 μg/mL, while 54.7% of patients who received non-carbapenem-containing regimens were successfully treated, although the difference was not statistically significant. In future studies, it would be valuable to expand the sample size to explore the efficacy of carbapenem in a larger group of patients with an MIC ≤4 μg/mL. Because of the retrospective nature and selection bias of our study and lack of appropriate antibiotics, we cannot comment on the effectiveness of appropriate empirical and definitive therapy among patients with CnSKP infection.

We acknowledge a number of limitations to this study. First, our analysis was a retrospective study, and it is possible that there may have been some degree of misclassification of the source of infection. Second, it was a single center study with a high incidence of CnSKP. Clone spread of KPC-2 and KPC-3 may make the hospital dissemination of CnSKP and influence therapy or prognosis; therefore, certain observations may not be applicable to other settings.

Conclusion
==========

CnSKP is emerging as a serious health care issue associated with high mortality rates and limited treatment options. This study demonstrated that prior hospitalization, urinary catheterization, receipt of immunosuppression agents, pulmonary disease, high APACHE II score, and exposure to carbapenems represent significant risk factors for the development of CnSKP-BSI. Neutropenia, low serum albumin, multiple organ dysfunction, respiratory failure, carbapenem-non-susceptibility, tigecycline therapy, and high APACHE II score are independent risk factors for mortality in patients with KP-BSI. With a higher observed mortality rate, we suggest that tigecycline may not be as effective as other antibiotics and that tigecycline should be used with caution for the treatment of multidrug-resistant KP.

Supplementary materials
=======================

###### 

Flowchart of the case selection process.

**Abbreviations:** BSI, bloodstream infection; CLSI, Clinical and Laboratory Standards Institute, CnSKP, carbapenem-nonsusceptible KP; CSKP, carbapenem-susceptible KP; KP, *Klebsiella pneumoniae*.

###### 

Annual incidence of *Klebsiella pneumoniae* bloodstream infections (KP and CnSKP) in hospital departments.

**Abbreviations:** CnSKP, carbapenem-nonsusceptible KP; CSKP, carbapenem-susceptible KP; GS, Department of General Surgery; HT, Department of Hematology; ICU, intensive care unit; ID, Department of Infectious Diseases; KP, *Klebsiella pneumoniae*; LT, Department of Liver Transplantation; NE, Department of Nephrology.

###### 

Analysis of risk factors for mortality in patients with BSI caused by CnSKP

                                                                            Univariate analysis                           Multivariable analysis                                     
  ------------------------------------------------------------------------- --------------------------------------------- ------------------------ --------- ------- ------- ------- --------
  Demographic                                                                                                                                                                        
   Gender, male, n (%)^q^                                                   42 (76.4)                                     39 (75)                  0.869                             
   Age, years, mean ± SD                                                    57.8±16.5                                     59.1±15.2                0.679                             
   Duration before bacteremia, days (IQR)                                   19 (6--32)                                    18 (7--49.5)             0.781                             
  Comorbid conditions                                                                                                                                                                
   CCI score (≥3), n (%)                                                    25 (45.5)                                     24 (46.2)                0.942                             
   Respiratory failure                                                      1 (1.8)                                       8 (15.4)                 0.014                             
   Heart failure                                                            1 (1.8)                                       5 (9.6)                  0.106                             
   Kidney failure                                                           3 (5.5)                                       4 (7.7)                  0.711                             
   Multiple organ failure                                                   5 (9.1)                                       20 (38.5)                \<0.001   0.004   5.498   1.727   17.504
  Prior ICU stay[a](#tfn9-idr-11-595){ref-type="table-fn"}                  35 (63.6)                                     37 (71.2)                0.407                             
  Invasive procedure or devices[a](#tfn9-idr-11-595){ref-type="table-fn"}   30 (54.5)                                     33 (63.5)                0.349                             
   Mechanical ventilation                                                   38 (69.1)                                     45 (86.5)                0.031                             
   Central venous catheterization                                           36 (65.5)                                     45 (86.5)                0.011     0.013   3.704   1.325   10.356
   Urinary catheterization                                                  42 (76.4)                                     47 (90.4)                0.053                             
  Invasive procedure or devices after BSI                                   18 (32.7)                                     9 (17.3)                 0.066                             
   Mechanical ventilation                                                   25 (45.5)                                     42 (80.8)                \<0.001                           
   Central venous catheterization                                           29 (52.7)                                     44 (84.6)                \<0.001                           
   Urinary catheterization                                                  36 (65.5)                                     47 (90.4)                0.002                             
  Prior receipt of antibiotics within 14 days before BSI                    [b](#tfn10-idr-11-595){ref-type="table-fn"}                                                              
   Number of antibiotics                                                    2 (1--3)                                      2 (2--3)                 0.157                             
  Severity of illness at the time of BSI                                                                                                                                             
   Mean APACHE II score ± SD                                                11.55±5.266                                   15.62±5.15               \<0.001   0.002   1.154   1.054   1.263
  Total antimicrobial regimen after BSI                                                                                                                                              
   Tigecycline                                                              30 (54.5)                                     34 (65.4)                0.253                             
   \<0.2 g/day                                                              14 (25.5)                                     17 (32.7)                0.790                             
   ≥0.2 g/day                                                               16 (29.1)                                     17 (32.7)                                                  
   Carbapenem                                                               37 (67.3)                                     34 (65.4)                0.836                             
   MIC \<4 μg/mL                                                            6 (16.2)                                      1 (2.9)                  0.109                             
   MIC ≥8 μg/mL                                                             31 (83.8)                                     31 (91.2)                0.482                             
   Aminoglycoside                                                           11 (20)                                       13 (25)                  0.535                             
   Fluoroquinolone                                                          9 (16.4)                                      10 (19.2)                0.698                             
   Appropriate empirical treatment                                          9 (16.4)                                      9 (17.3)                 0.896                             
   1) Monotherapy                                                           24 (43.6)                                     14 (26.9)                0.071                             
   2) Combination therapy                                                   31 (56.4)                                     38 (73.1)                                                  
   Appropriate definitive treatment                                         20 (36.4)                                     25 (48.1)                0.220                             
   1) No active drug                                                        34 (61.8)                                     27 (51.9)                0.236                             
   2) At least two active drugs                                             3 (5.5)                                       6 (11.5)                                                   
   3) One active drug                                                       18 (32.7)                                     19 (36.5)                                                  
  Antimicrobial regimen                                                                                                                                                              
   1) Tigecycline monotherapy                                               6 (10.9)                                      2 (3.8)                  0.272                             
   2) Tigecycline combination therapy                                       24 (43.6)                                     32 (61.5)                0.064                             
   APACHE II \<15                                                           16 (66.7)                                     16 (50)                  0.212                             
   APACHE II ≥15                                                            8 (33.3)                                      16 (50)                                                    
   3) Carbapenem monotherapy                                                11 (20)                                       6 (11.5)                 0.231                             
   4) Carbapenem-containing regimen                                         26 (47.3)                                     28 (53.8)                0.497                             
   MIC \<4 μg/mL                                                            3 (11.5)                                      1 (3.6)                  0.342                             
   MIC ≥8 μg/mL                                                             23 (88.5)                                     25 (89.3)                1.000                             

**Notes:** Data are expressed as number (%) unless otherwise stated;

During the 30 days preceding BSI onset

during the 14 days preceding BSI onset.

**Abbreviations:** APACHE, Acute Physiology and Chronic Health Evaluation; BSI, bloodstream infection; CCI, Charlson comorbidity index; CI, confidence interval; CnSKP, carbapenem-nonsusceptible KP; CSKP, carbapenem-susceptible KP; ICU, intensive care unit; KP, *Klebsiella pneumoniae*; IQR, interquartile range; MIC, minimum inhibitory concentration; SD, standard deviation.
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###### 

Clinical and demographic characteristics of patients with BSI caused by *Klebsiella pneumoniae*

                                                                                              Univariate analysis   Multivariable analysis                                       
  ------------------------------------------------------------------------------------------- --------------------- ------------------------ --------- --------- ------- ------- --------
  Demographic                                                                                                                                                                    
   Gender, male, n (%)                                                                        198 (67.6)            101 (74.8)               0.129                               
   Age, years, mean ± SD                                                                      58.7±16.4             59.1±15.4                0.799                               
   Duration before bacteremia, days (IQR)                                                     4 (1--16)             16 (6--37)               \<0.001                             
  Preexisting medical conditions                                                                                                                                                 
   Pulmonary disease                                                                          33 (11.3)             51 (37.8)                \<0.001   0.008     2.599   1.280   5.280
   Hepatic disease                                                                            90 (30.8)             30 (22.2)                0.066                               
   Hepatapostema                                                                              45 (15.4)             6 (4.4)                  0.001                               
   Solid tumor                                                                                60 (10.5)             13 (9.6)                 0.006                               
  CCI score (≥3), n (%)                                                                       105 (35.8)            60 (44.8)                0.078                               
  Likely source of bacteremia                                                                                                                                                    
   Catheter-related                                                                           7 (2.4)               9 (6.7)                  0.030                               
   Pneumonia                                                                                  69 (23.5)             67 (49.7)                \<0.001                             
   Intra-abdominal                                                                            123 (42)              41 (30.4)                0.022                               
   Urinary tract                                                                              6 (2.0)               1 (0.7)                  0.441                               
   Intracranial infection                                                                     3 (1.0)               4 (3.0)                  0.214                               
   Mixed infection                                                                            13 (4.4)              14 (10.4)                0.019                               
   Primary bloodstream infection                                                              69 (23.5)             6 (4.4)                  \<0.001                             
  Hospital-acquired infection                                                                 253 (86.3)            135 (100)                \<0.001                             
  Prior hospitalization[a](#tfn1a-idr-11-595){ref-type="table-fn"}                            127 (43.3)            92 (68.1)                \<0.001   0.004     2.395   1.326   4.328
  Prior ICU stay[b](#tfn1b-idr-11-595){ref-type="table-fn"}                                   52 (17.7)             87 (64.4)                \<0.001                             
  Prior surgery[b](#tfn1b-idr-11-595){ref-type="table-fn"}                                    95 (32.4)             65 (48.1)                0.002                               
   Previous transplantations[b](#tfn1b-idr-11-595){ref-type="table-fn"}                       5 (1.7)               21 (15.6)                \<0.001                             
  Invasive procedure or devices[b](#tfn1b-idr-11-595){ref-type="table-fn"}                    96 (32.8)             74 (54.8)                \<0.001                             
   Mechanical ventilation                                                                     58 (19.8)             100 (74.1)               \<0.001                             
   Central venous catheterization                                                             64 (21.8)             101 (74.8)               \<0.001                             
   Urinary catheterization                                                                    77 (26.3)             110 (81.5)               \<0.001   \<0.001   5.277   2.748   10.134
   Percutaneous tube                                                                          61 (20.8)             58 (43)                  \<0.001                             
  Prior hemodialysis[b](#tfn1b-idr-11-595){ref-type="table-fn"}                               19 (6.5)              36 (26.7)                \<0.001                             
  Prior chemotherapy or radiotherapy[b](#tfn1b-idr-11-595){ref-type="table-fn"}               38 (13)               6 (4.4)                  0.007                               
  Prior corticosteroid use[b](#tfn1b-idr-11-595){ref-type="table-fn"}                         39 (13.3)             42 (31.1)                \<0.001                             
  Prior immunosuppressant use[b](#tfn1b-idr-11-595){ref-type="table-fn"}                      21 (7.2)              28 (20.7)                \<0.001   0.001     4.093   1.734   9.661
  Use of antibiotics within 14 days prior to BSI[c](#tfn1c-idr-11-595){ref-type="table-fn"}   128 (43.7)            120 (88.9)               \<0.001   0.007     2.739   1.311   5.721
   Number of antibiotics                                                                      0 (0--1)              2 (1--3)                 \<0.001                             
   Cephalosporin                                                                              12 (4.1)              17 (12.6)                0.001                               
   β-lactam and/or β-lactamase inhibitor                                                      84 (28.7)             66 (48.9)                \<0.001                             
   Tigecycline                                                                                10 (3.4)              26 (19.4)                \<0.001                             
   Carbapenem                                                                                 36 (12.3)             73 (54.1)                \<0.001   \<0.001   4.591   2.331   9.044
   Fluoroquinolone                                                                            22 (7.5)              25 (18.5)                0.001                               
  Laboratory examination                                                                                                                                                         
   Serum total protein, g/L                                                                   61.8 (54.7--66.8)     57.9 (53.0--65.4)        0.023                               
   Serum albumin \<30 g/L                                                                     93 (31.7)             52 (38.5)                0.169                               
  Mean APACHE II score ± SD                                                                   8.9±4.4               12.6±5.6                 \<0.001   0.001     1.100   1.042   1.162

**Notes:** Data are expressed as numbers (%) unless otherwise stated;

During the 3 months preceding the BSI onset;

during the 30 days preceding BSI onset.

during the 14 days preceding BSI onset.

**Abbreviations:** APACHE, Acute Physiology and Chronic Health Evaluation; BSI, bloodstream infection; CCI, Charlson comorbidity index; CI, confidence interval; CnSKP, carbapenem-nonsusceptible *Klebsiella pneumoniae*; CSKP, carbapenem-susceptible *Klebsiella pneumoniae*; ICU, intensive care unit; IQR, interquartile range; SD, standard deviation.

###### 

Analysis of risk factors for 30-day mortality in 370 patients with KP-BSI

                                                                                                       Univariate analysis   Multivariable analysis                                     
  ---------------------------------------------------------------------------------------------------- --------------------- ------------------------ --------- ------- ------- ------- --------
  Demographic                                                                                                                                                                           
   Gender, male, n (%)                                                                                 202 (69.2)            57 (73.1)                0.504                             
   Age, years, mean ± SD                                                                               58.5±16.6             58.6±15.8                0.951                             
   Hospital stay before bacteremia, days (IQR)                                                         5 (1--19)             13.5 (3--30.25)          0.001                             
  Preexisting medical conditions                                                                                                                                                        
   Pulmonary disease                                                                                   43 (14.7)             25 (32.1)                \<0.001                           
   Hepatic disease                                                                                     87 (29.8)             16 (20.8)                0.117                             
   Hepatapostema                                                                                       46 (15.8)             2 (2.6)                  0.002                             
  Comorbid conditions                                                                                                                                                                   
   CCI score (≥3) n (%)                                                                                96 (32.9)             38 (48.7)                0.010                             
   Respiratory failure                                                                                 6 (2.1)               13 (16.7)                \<0.001   0.014   5.266   1.396   19.866
   Multiple organ failure                                                                              12 (4.1)              30 (38.5)                \<0.001   0.008   4.104   1.438   11.709
  Hospital-acquired infection                                                                          254 (87)              78 (100)                 0.001                             
  Prior hospitalization[a](#tfn4-idr-11-595){ref-type="table-fn"}                                      135 (46.2)            49 (62.8)                0.009                             
  Prior ICU stay[b](#tfn5-idr-11-595){ref-type="table-fn"}                                             75 (25.7)             44 (56.4)                \<0.001                           
  Prior surgery[b](#tfn5-idr-11-595){ref-type="table-fn"}                                              106 (36.3)            36 (46.2)                0.112                             
   Previous transplantation[b](#tfn5-idr-11-595){ref-type="table-fn"}                                  10 (3.4)              13 (16.7)                \<0.001                           
  Invasive procedure or devices[b](#tfn5-idr-11-595){ref-type="table-fn"}                              105 (36.0)            43 (55.1)                0.002                             
   Mechanical ventilation[b](#tfn5-idr-11-595){ref-type="table-fn"}                                    82 (28.1)             54 (69.2)                \<0.001                           
   Central venous catheterization[b](#tfn5-idr-11-595){ref-type="table-fn"}                            86 (29.5)             52 (66.7)                \<0.001                           
   Urinary catheterization[b](#tfn5-idr-11-595){ref-type="table-fn"}                                   100 (34.2)            56 (71.8)                \<0.001                           
   Percutaneous tube[b](#tfn5-idr-11-595){ref-type="table-fn"}                                         75 (25.7)             34 (43.6)                0.002                             
  Invasive procedure or devices after BSI[c](#tfn6-idr-11-595){ref-type="table-fn"}                    79 (27.1)             16 (20.5)                0.240                             
   Mechanical ventilation[c](#tfn6-idr-11-595){ref-type="table-fn"}                                    54 (18.5)             53 (67.9)                \<0.001                           
   Central venous catheterization[c](#tfn6-idr-11-595){ref-type="table-fn"}                            73 (25.0)             57 (73.1)                \<0.001                           
   Urinary catheterization[c](#tfn6-idr-11-595){ref-type="table-fn"}                                   103 (35.3)            62 (79.5)                \<0.001                           
  Prior hemodialysis[b](#tfn5-idr-11-595){ref-type="table-fn"}                                         25 (8.6)              18 (23.1)                \<0.001                           
  Prior corticosteroid use[b](#tfn5-idr-11-595){ref-type="table-fn"}                                   39 (13.4)             25 (32.1)                \<0.001                           
  Prior immunosuppressant use[b](#tfn5-idr-11-595){ref-type="table-fn"}                                24 (8.2)              16 (20.5)                0.002                             
  Hemodialysis after BSI                                                                               19 (6.5)              18 (23.1)                \<0.001                           
  Corticosteroid use after BSI                                                                         46 (15.8)             27 (34.6)                \<0.001                           
  Immunosuppressant use after BSI                                                                      18 (6.2)              11 (14.1)                0.020                             
  Prior receipt of antibiotics within 14 days prior to BSI[c](#tfn6-idr-11-595){ref-type="table-fn"}                                                                                    
   Number of antibiotics                                                                               0 (0--2)              2 (1--3)                 \<0.001                           
   Cephalosporin                                                                                       20 (6.8)              8 (10.3)                 0.312                             
   β-lactam and/or β-lactamase inhibitor                                                               88 (30.1)             40 (51.3)                \<0.001                           
   Tigecycline                                                                                         17 (5.8)              14 (17.9)                0.001                             
   Carbapenem                                                                                          52 (17.8)             36 (46.2)                \<0.001                           
   Fluoroquinolone                                                                                     29 (9.9)              7 (9.0)                  0.800                             
  Carbapenem nonsusceptible                                                                            55 (18.8)             52 (66.7)                \<0.001   0.009   2.847   1.302   6.227
  Laboratory examination                                                                                                                                                                
   Neutropenia                                                                                         21 (7.2)              12 (15.4)                0.024     0.008   4.104   1.438   11.709
   Serum fibrinogen, d                                                                                 3.9 (2.7--5.1)        3.5 (1.7--4.7)           0.015                             
   Serum albumin \<30 g/L                                                                              91 (31.2)             34 (43.6)                0.039                             
  Severity of illness at time of BSI                                                                                                                                                    
   Mean APACHE II score ± SD                                                                           9.2±4.4               14.2±5.8                 \<0.001   0.018   1.990   0.988   4.007
  Total antimicrobial regimen after BSI                                                                                                                                                 
   β-lactam and/or β-lactamase inhibitor                                                               144 (49.3)            36 (46.2)                0.620                             
   Tigecycline                                                                                         41 (14.0)             43 (55.1)                \<0.001   0.034   2.300   1.065   4.969
   \<0.2 g/day                                                                                         20 (6.8)              21 (26.9)                                                  
   ≥0.2 g/day                                                                                          21 (7.2)              22 (28.2)                                                  
   a. Monotherapy                                                                                      7 (2.4)               13 (3.9)                                                   
   b. Combination therapy                                                                              34 (11.6)             40 (51.9)                                                  
   Carbapenem                                                                                          198 (67.8)            56 (71.8)                0.500                             
   Fluoroquinolone                                                                                     45 (15.5)             14 (17.9)                0.595                             
   Appropriate empirical treatment                                                                     237 (81.2)            33 (42.3)                \<0.001                           
   1) Monotherapy                                                                                      232 (79.5)            33 (42.3)                \<0.001                           
   2) Combination therapy                                                                              60 (20.5)             45 (57.7)                                                  
   Appropriate definitive treatment                                                                    246 (84.2)            50 (64.1)                \<0.001                           

**Notes:** Data are expressed as numbers (%) unless otherwise stated;

During the 3 months preceding BSI onset;

during the 30 days preceding BSI onset;

during the 14 days preceding BSI onset.

**Abbreviations:** APACHE, Acute Physiology and Chronic Health Evaluation; BSI, bloodstream infection; CCI, Charlson comorbidity index; CI, confidence interval; CnSKP, carbapenem-nonsusceptible KP; CSKP, carbapenem-susceptible KP; ICU, intensive care unit; KP, *Klebsiella pneumoniae*; IQR, interquartile range; SD, standard deviation.
